Pharm-Olam International

Pharm-Olam International is a contract research organization that provides clinical trial services to pharmaceutical, biotechnology, and medical device companies. The firm offers end-to-end solutions that cover study design, site selection, patient recruitment, monitoring, data management, statistical analysis, and regulatory support. Its service portfolio spans early-phase trials, late-phase studies, and post-marketing surveillance projects. By integrating these functions, Pharm-Olam aims to streamline drug development timelines for its sponsors.

Headquartered in the United States, the company maintains a geographic footprint that includes offices in North America, Europe, and the Asia-Pacific region. This global presence allows Pharm-Olam to manage multinational clinical trials and access diverse patient populations. The organization serves sponsors working on a range of therapeutic areas, including oncology, cardiology, central nervous system disorders, and infectious diseases. Its client base comprises both large multinational corporations and emerging biotech firms seeking specialized clinical expertise. The company also provides consulting services related to trial feasibility, site activation, and risk-based monitoring approaches. These capabilities help sponsors optimize resource allocation and improve study efficiency.

Pharm-Olam is recognized for its depth of experience in early-phase clinical development, especially first-in-human and proof-of-concept studies. Therapeutic area specialists within the company collaborate with sponsors to refine trial protocols and address regulatory requirements set by agencies such as the FDA and EMA. In February 2016, the firm disclosed a security incident involving the unauthorized release of employee W-2 forms, which exposed names, addresses, Social Security numbers, and wage information. Following the breach, Pharm-Olam launched an internal investigation, notified law enforcement and relevant authorities, and offered affected individuals complimentary identity protection services for one year. The episode underscored the importance of robust data protection measures within the clinical research sector.